Found: 111
Select item for more details and to access through your institution.
Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 2, p. 763, doi. 10.1007/s40121-021-00410-0
- By:
- Publication type:
- Article
Preoperative Radiotherapy for Resectable Rectal Cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 2000, v. 284, n. 8, p. 1008, doi. 10.1001/jama.284.8.1008
- By:
- Publication type:
- Article
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
- Published in:
- Liver International, 2014, v. 34, p. 85, doi. 10.1111/liv.12395
- By:
- Publication type:
- Article
How to optimize HCV therapy in genotype 1 patients: predictors of response.
- Published in:
- Liver International, 2013, v. 33, p. 23, doi. 10.1111/liv.12053
- By:
- Publication type:
- Article
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
- Published in:
- Liver International, 2012, v. 32, n. 9, p. 1443, doi. 10.1111/j.1478-3231.2012.02842.x
- By:
- Publication type:
- Article
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
- Published in:
- Liver International, 2012, p. 2, doi. 10.1111/j.1478-3231.2011.02703.x
- By:
- Publication type:
- Article
Should cirrhosis change our attitude towards treating non-hepatic cancer?
- Published in:
- Liver International, 2012, v. 32, n. 1, p. 21, doi. 10.1111/j.1478-3231.2011.02629.x
- By:
- Publication type:
- Article
Management of hepatitis B virus infection in the underprivileged world.
- Published in:
- 2011
- By:
- Publication type:
- Editorial
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.
- Published in:
- Liver International, 2011, v. 31, n. 4, p. 507, doi. 10.1111/j.1478-3231.2011.02453.x
- By:
- Publication type:
- Article
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.
- Published in:
- Liver International, 2011, v. 31, p. 36, doi. 10.1111/j.1478-3231.2010.02382.x
- By:
- Publication type:
- Article
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.
- Published in:
- Liver International, 2010, v. 30, n. 3, p. 342, doi. 10.1111/j.1478-3231.2009.02188.x
- By:
- Publication type:
- Article
HCV genotypes in Sicily: Is there any evidence of a shift?
- Published in:
- Journal of Medical Virology, 2009, v. 81, n. 6, p. 1040, doi. 10.1002/jmv.21498
- By:
- Publication type:
- Article
Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: The Camporeale model.
- Published in:
- Journal of Medical Virology, 2008, v. 80, n. 10, p. 1723, doi. 10.1002/jmv.21276
- By:
- Publication type:
- Article
Modulation of epitope‐specific anti‐hepatitis C virus E2 (anti‐HCV/E2) antibodies by anti‐viral treatment.
- Published in:
- Journal of Medical Virology, 2006, v. 78, n. 10, p. 1304
- By:
- Publication type:
- Article
SARS-CoV-2 Viral Load, IFNλ Polymorphisms and the Course of COVID-19: An Observational Study.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 10, p. 3315, doi. 10.3390/jcm9103315
- By:
- Publication type:
- Article
Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.926236
- By:
- Publication type:
- Article
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 5, p. 604, doi. 10.1111/apt.16763
- By:
- Publication type:
- Article
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.
- Published in:
- 1992
- By:
- Publication type:
- journal article
Delta infection in hepatocellular carcinoma positive for hepatitis B surface antigen.
- Published in:
- 1984
- By:
- Publication type:
- journal article
Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The hepatic expression of vitamin d receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
- Published in:
- Infection, 2018, v. 46, n. 5, p. 607, doi. 10.1007/s15010-018-1157-x
- By:
- Publication type:
- Article
Current and future challenges in HCV: insights from an Italian experts panel.
- Published in:
- Infection, 2018, v. 46, n. 2, p. 147, doi. 10.1007/s15010-017-1093-1
- By:
- Publication type:
- Article
Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance.
- Published in:
- Digestive Diseases, 2009, v. 27, n. 2, p. 142, doi. 10.1159/000218346
- By:
- Publication type:
- Article
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2408, doi. 10.1111/dom.14168
- By:
- Publication type:
- Article
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease.
- Published in:
- PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0142210
- By:
- Publication type:
- Article
Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0110857
- By:
- Publication type:
- Article
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0087523
- By:
- Publication type:
- Article
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074089
- By:
- Publication type:
- Article
NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0068364
- By:
- Publication type:
- Article
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0070016
- By:
- Publication type:
- Article
Serum γ-glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0051165
- By:
- Publication type:
- Article
Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?
- Published in:
- 2012
- By:
- Publication type:
- journal article
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 90, doi. 10.3390/cancers13010090
- By:
- Publication type:
- Article
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2132, doi. 10.3390/cancers12082132
- By:
- Publication type:
- Article
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
- Published in:
- PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0243590
- By:
- Publication type:
- Article
Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
- Published in:
- Annali dell'Istituto Superiore di Sanita, 2020, v. 56, n. 3, p. 325, doi. 10.4415/ANN_20_03_10
- By:
- Publication type:
- Article
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, p. 1, doi. 10.1186/s12933-018-0670-7
- By:
- Publication type:
- Article
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.
- Published in:
- Liver International, 2024, v. 44, n. 11, p. 2890, doi. 10.1111/liv.16064
- By:
- Publication type:
- Article
Forecasting the long‐term impact of COVID‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
- Published in:
- Liver International, 2023, v. 43, n. 12, p. 2615, doi. 10.1111/liv.15712
- By:
- Publication type:
- Article
Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.
- Published in:
- Liver International, 2022, v. 42, n. 1, p. 26, doi. 10.1111/liv.15070
- By:
- Publication type:
- Article
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease.
- Published in:
- Liver International, 2021, v. 41, n. 11, p. 2712, doi. 10.1111/liv.15016
- By:
- Publication type:
- Article
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
- Published in:
- Liver International, 2021, v. 41, n. 5, p. 934, doi. 10.1111/liv.14808
- By:
- Publication type:
- Article
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.
- Published in:
- Liver International, 2021, v. 41, n. 4, p. 649, doi. 10.1111/liv.14796
- By:
- Publication type:
- Article
PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD.
- Published in:
- Liver International, 2021, v. 41, n. 2, p. 321, doi. 10.1111/liv.14711
- By:
- Publication type:
- Article
Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel.
- Published in:
- Liver International, 2020, v. 40, n. 11, p. 2590, doi. 10.1111/liv.14627
- By:
- Publication type:
- Article
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis.
- Published in:
- Liver International, 2020, v. 40, n. 11, p. 2820, doi. 10.1111/liv.14608
- By:
- Publication type:
- Article
Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
- Published in:
- Liver International, 2020, v. 40, n. 7, p. 1545, doi. 10.1111/liv.14408
- By:
- Publication type:
- Article
Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy.
- Published in:
- Liver International, 2020, v. 40, n. 3, p. 530, doi. 10.1111/liv.14250
- By:
- Publication type:
- Article
Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study).
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2240, doi. 10.1111/liv.14242
- By:
- Publication type:
- Article